Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies

IntroductionZabedosertib, the interleukin-1 receptor-associated kinase-4 (IRAK4) inhibitor, is in clinical development as an oral therapeutic for immune-mediated inflammatory diseases and was thoroughly investigated in several phase 1 studies in healthy male volunteers.MethodsPharmacokinetics, safet...

Повний опис

Бібліографічні деталі

Автори:	Maximilian Feldmüller, Stefan J. Jodl, Bart Ploeger, Andrea Wagenfeld, Herbert Wiesinger, Frank S. Zollmann, Stefan Klein, Ruiping Zhang, Beate Rohde, Joachim Höchel
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2025-05-01
Серія:	Frontiers in Pharmacology
Предмети:	safety pharmacokinetics pharmacodynamics IRAK4 IRAK4 inhibitor immune-mediated inflammatory disorders pharmacodynamics
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1521505/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!